Spread the love

A recent study from the “Department of Laboratory Medicine, University of California San Francisco, San Francisco, California 94143, USA;  and Department of Haematology, University of Cambridge, Cambridge CB2 OAH, UK” shows that Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoid leukaemia. This study was published in the 10 March  2015 issue of Online journal Nature Communication”  by Prof Müschen M, Buchner M and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based therapy for leukaemia: MiRNA-370 suppresess B-cell lineage acute lymphoid leukaemia via down regulation of its target gene 


This study suggests an miRNA-based therapy for human leukaemia: MiRNA-370, by suppressing the expression of its target gene, it may inhibit the progression of B-cell lineage acute leukaemia. Thus, pharmacological formulations encompassing “MiRNA-370 activators” may be used to inhibit B-cell lineage acute leukaemia.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, MiRNA-based therapy for leukaemia: MiRNA-370 suppresess B-cell lineage acute lymphoid leukaemia via down regulation of its target gene, 22/April/2014, 18.54,Genome-2-Bio-MedicineDiscoverycenter (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Undisclosed information: How MiRNA-370 inhibits the progression of B-cell lineage acute lymphoid leukaemia.

Spread the love